McClure Matthew W. 4
4 · Aligos Therapeutics, Inc. · Filed Sep 12, 2023
Insider Transaction Report
Form 4
McClure Matthew W.
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-09-08+48,000→ 48,000 totalExercise: $0.84Exp: 2033-09-08→ Common Stock (48,000 underlying)
Footnotes (1)
- [F1]1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.